Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1
Navneet Singh(Post Graduate Institute of Medical Education and Research), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Natasha B. Leighl(Princess Margaret Cancer Centre), Tanyanika Phillips(Georgetown University), Nofisat Ismaila(American Society of Clinical Oncology), Ishmael Jaiyesimi(Beaumont Hospital, Royal Oak), Hirva Mamdani(Wayne State University)
Cited by 51
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805